AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-hodgkin Lymphoma, Unspecified
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically confirmed FL or DLBCL fro the following diagnoses by 2016 WHO classification of lymphoid neoplasms 2) Must have received at least one prior systemic treatment regimen containing an anti-CD20-directed therapy for DLBCL or FL. Patients must have either relapsed or have become refractory to a prior regimen as defined below. 3) Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
You may not be eligible for this study if the following are true:
-
1) Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies 2) Prior treatment with polatuzumab vedotin 3) Current > Grade 1 peripheral neuropathy 4) Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
